難治性多発性骨髄腫 - 世界の臨床試験のレビュー（2024年）

当レポートでは、難治性多発性骨髄腫の臨床試験について調査分析し、各国の臨床試験数と平均登録数のデータや、主要企業のレビューと関連する臨床試験のリストなどを提供しています。

目次

表のリスト

図表のリスト

• レポートガイダンス
• GlobalDataの臨床試験レポートのカバー範囲
• 臨床試験：地域別
• 臨床試験と平均登録数：国別
• アジア太平洋の臨床試験に寄与している上位5ヶ国
• 欧州の臨床試験に寄与している上位5ヶ国
• 北米の臨床試験に寄与している上位国
• 中東・アフリカの臨床試験に寄与している上位5ヶ国
• 中南米の臨床試験に寄与している上位5ヶ国
• G7諸国による臨床試験：腫瘍学の臨床試験に占める難治性多発性骨髄腫の割合
• G7諸国の臨床試験：フェーズ別
• G7諸国の臨床試験：試験ステータス別
• E7諸国による臨床試験：腫瘍学の臨床試験に占める難治性多発性骨髄腫の割合
• E7諸国の臨床試験：フェーズ別
• E7諸国の臨床試験：試験ステータス別
• 臨床試験：フェーズ別
• 進行中の試験：フェーズ別
• 臨床試験：試験ステータス別
• 臨床試験：エンドポイントステータス別
• 一定期間にわたって採用された被験者
• 臨床試験：スポンサータイプ別
• 著名なスポンサー
• 難治性多発性骨髄腫治療の臨床試験に参加している主要企業
• 著名な薬剤
• 難治性多発性骨髄腫に関する最新の臨床試験ニュース
• 2024年11月14日：Blenrepが再発性/難治性多発性骨髄腫を対象としたDreamm-7フェーズ3試験で全生存率の向上を示す
• 2024年11月6日：CarsgenがASH 2024 Annual CongressでZevor-Celを発表
• 2024年11月6日：CarsgenがASH 2024 Annual CongressでCT0590を発表
• 2024年11月5日：Ichnos Glenmark Innovation（IGI）、今後のASHでr/rMMにおける三重特異性Isb 2001のフェーズ1試験のデータを初公開すると発表
• 2024年11月5日：Ichnos Glenmark Innovation（IGI）、今後のASHでr/r MMにおける三重特異性ISB 1442のフェーズ1試験のデータを初公開すると発表
• 2024年11月5日：Antengene、Selinexorのシグナル伝達の潜在的な臨床的ブレークスルーに関する2つの後期段階の研究結果をASH 2024で発表
• 2024年11月5日：Poseida Therapeutics、SITC 2024とASH 2024で研究中の同種CAR-T細胞療法に関する臨床と前臨床データを発表
• 2024年11月5日：Arcellx、第66回ASH年次総会で多発性骨髄腫患者を対象としたフェーズ1試験とiMMagine-1試験の臨床データを発表予定
• 2024年10月8日：Aurigene Oncology、多発性骨髄腫に対する新しい自己CAR-T細胞療法のインド初試験のフェーズ1試験の有望な結果を発表
• 2024年9月27日：Talveyの新規併用療法が、R/R多発性骨髄腫のトリプルクラス難治性患者において高い奏効率と持続的な奏効を示唆
• 2024年9月27日：Tecvayliの新規併用療法が、R/R多発性骨髄腫のトリプルクラス難治性患者において高い奏効率と持続的な奏効を示唆
• 2024年9月27日：IASO Bio、2024 IMS Annual MeetingにてEquecabtagene Autoleucelで治療した腎機能障害のあるR/Rmm患者の転帰を発表
• 2024年9月27日：TalveyとDarzalex Fasproをベースとした併用療法が、再発性/難治性の多発性骨髄腫患者に深く持続的な反応を示す
• 2024年9月27日：Poseida、RRMM患者における全奏効率が高い同種CAR-T療法P-BCMA-ALLO1のフェーズ1中間試験の良好な結果を報告
• 2024年9月17日：再発性/難治性多発性骨髄腫に対するBlenrep（belantamab mafodotin）併用療法が日本で規制当局の審査を受理
• 2024年9月16日：中国、多発性骨髄腫の治療薬としてBlenrepとBorDexにBTDを付与
• 2024年9月16日：FDA、PoseidaのCAR-T細胞療法P-BCMA-ALLO1にRMATを付与
• 2024年9月11日：IGI、再発性/難治性多発性骨髄腫に対するIGIの革新的な三特異性抗体ISB 2001に関する論文をNature Cancerで公開すると発表
• 2024年9月5日：Poseida、再発性/難治性多発性骨髄腫における同種CAR-T P-BCMA-ALLO1のフェーズ1試験のデータを21st IMS Annual Meetingで発表
• 臨床試験プロファイルのスナップショット

List of Tables

• Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Region, 2024*
• Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024*
• Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2024*
• Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2024*
• Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2024*
• Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024*
• Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2024*
• Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2024*
• Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024*
• Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase, 2024*
• Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase 2024*
• Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023
• Refractory Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024*

List of Figures

• Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Region (%), 2024*
• Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024*
• Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries (%), 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2024*
• Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2024*
• Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2024*
• Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024*
• Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2024*
• Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2024*
• Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024*
• Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase (%), 2024*
• Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase, 2024*
• Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023
• Refractory Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024*
• Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024*
• GlobalData Methodology

GlobalData's clinical trial report, "Refractory Multiple Myeloma - Global Clinical Trials Review, 2024" provides an overview of Refractory Multiple Myeloma Clinical trials scenario. This report provides top line data relating to the clinical trials on Refractory Multiple Myeloma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

List of Tables

List of Figures

• Report Guidance
• GlobalData Clinical Trials Report Coverage
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Top Five Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Five Countries Contributing to Clinical Trials in Middle East and Africa
• Top Five Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Countries: Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Refractory Multiple Myeloma Therapeutics Clinical Trials
• Prominent Drugs
• Latest Clinical Trials News on Refractory Multiple Myeloma
• Nov 14, 2024: Blenrep Shows Overall Survival Benefit in Head-To-Head Dreamm-7 Phase III Trial for Relapsed/Refractory Multiple Myeloma
• Nov 06, 2024: Carsgen to Present Zevor-Cel at ASH 2024 Annual Congress
• Nov 06, 2024: Carsgen to Present CT0590 at ASH 2024 Annual Congress
• Nov 05, 2024: Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific Isb 2001 in r/rMM at Upcoming ASH
• Nov 05, 2024: Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 1442 in r/r MM at Upcoming ASH
• Nov 05, 2024: Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024
• Nov 05, 2024: Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024
• Nov 05, 2024: Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Multiple Myeloma at the 66th ASH Annual Meeting
• Oct 08, 2024: Aurigene Oncology Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
• Sep 27, 2024: Novel Combination of Talvey Suggests High Response Rates and Durable Responses in Triple-Class Refractory Patients with R/R Multiple Myeloma
• Sep 27, 2024: Novel Combination of Tecvayli Suggests High Response Rates and Durable Responses in Triple-Class Refractory Patients with R/R Multiple Myeloma
• Sep 27, 2024: IASO Bio Presented the Outcomes of R/Rmm Patients with Renal Impairment Treated with Equecabtagene Autoleucel at 2024 IMS Annual Meeting
• Sep 27, 2024: Talvey and Darzalex Faspro Based Combination Shows Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
• Sep 27, 2024: Poseida Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in RRMM Patients
• Sep 17, 2024: Blenrep (belantamab mafodotin) Combinations in Relapsed/Refractory Multiple Myeloma Accepted for Regulatory Review in Japan
• Sep 16, 2024: China grants BTD to Blenrep with BorDex for multiple myeloma
• Sep 16, 2024: FDA grants RMAT to Poseida's CAR-T cell therapy P-BCMA-ALLO1
• Sep 11, 2024: IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma
• Sep 05, 2024: Poseida to Present Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed/Refractory Multiple Myeloma at 21st IMS Annual Meeting
• Clinical Trial Profile Snapshots
• Abbreviations
• Definitions
• Research Methodology
• Secondary Research
• About GlobalData
• Contact Us
• Disclaimer
• Source